CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.46
−1.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -72.9%
- EBIT
- -59.4%
- EPS
- -36.1%
- Free cash flow
- -49.7%
- Operating cash flow
- -49.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +20.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -75.1%
- Net income
- -95.3%
- EPS
- -60.3%
- Free cash flow
- -54.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026